Molecular Endocrinology, Vol 10, 534-543, Copyright © 1996 by Endocrine Society

ARTICLES

Activin signaling through activin receptor type II causes the cachexia- like symptoms in inhibin-deficient mice

KA Coerver, TK Woodruff, MJ Finegold, J Mather, A Bradley and MM Matzuk
Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA.

Activins and inhibins, members of the transforming growth factor-beta superfamily, are involved in diverse physiological and developmental processes. We have previously shown that mice deficient in alpha- inhibin develop gonadal sex cord-stromal tumors at an early age. The tumor development is rapidly followed by a wasting syndrome that includes severe weight loss, hepatocellular necrosis around the central vein, and depletion of the parietal cells in the glandular stomach. The liver histology in inhibin-deficient mice is similar to the pathological effects of short-term treatment of rats and mice with recombinant activin A. Consistent with these findings, we have shown that the gonadal tumors in the inhibin-deficient mice secrete high levels of activins. In addition, Northern blot analysis has localized activin receptor type II (ActRII) to the liver. Based on these studies, we postulated that tumor-produced activins act through ActRII to cause the wasting syndrome in inhibin-deficient mice. To test this hypothesis and determine the significance of elevated levels of activin signaling through ActRII in vivo, we generated compound homozygous mutant mice deficient in both alpha-inhibin and ActRII. Despite the continued development of gonadal sex cord-stromal tumors and elevated serum levels of activin A and B, the compound homozygous mutant mice suffered no unusual weight loss, and the stomachs and livers of the majority of the mice were histologically normal. These results demonstrate that increased levels of activin signaling through ActRII in hepatocytes and the glandular stomach causes the hepatocellular necrosis and depletion of parietal cells in the glandular stomach as well as the severe weight loss in vivo.

This article has been cited by other articles:

				M. A. Edson, A. K. Nagaraja, and M. M. Matzuk The Mammalian Ovary from Genesis to Revelation Endocr. Rev., October 1, 2009; 30(6): 624 - 712. [Abstract] [Full Text] [PDF]

				L. Li, J. J. Shen, J. C. Bournat, L. Huang, A. Chattopadhyay, Z. Li, C. Shaw, B. H. Graham, and C. W. Brown Activin Signaling: Effects on Body Composition and Mitochondrial Energy Metabolism Endocrinology, August 1, 2009; 150(8): 3521 - 3529. [Abstract] [Full Text] [PDF]

				B. Barakat, A. E O'Connor, E. Gold, D. M de Kretser, and K. L Loveland Inhibin, activin, follistatin and FSH serum levels and testicular production are highly modulated during the first spermatogenic wave in mice Reproduction, September 1, 2008; 136(3): 345 - 359. [Abstract] [Full Text] [PDF]

				S. A. Pangas, X. Li, L. Umans, A. Zwijsen, D. Huylebroeck, C. Gutierrez, D. Wang, J. F. Martin, S. P. Jamin, R. R. Behringer, et al. Conditional Deletion of Smad1 and Smad5 in Somatic Cells of Male and Female Gonads Leads to Metastatic Tumor Development in Mice Mol. Cell. Biol., January 1, 2008; 28(1): 248 - 257. [Abstract] [Full Text] [PDF]

				K. L. Jones, A. Mansell, S. Patella, B. J. Scott, M. P. Hedger, D. M. de Kretser, and D. J. Phillips Activin A is a critical component of the inflammatory response, and its binding protein, follistatin, reduces mortality in endotoxemia PNAS, October 9, 2007; 104(41): 16239 - 16244. [Abstract] [Full Text] [PDF]

				Q. Li, J. M. Graff, A. E. O'Connor, K. L. Loveland, and M. M. Matzuk SMAD3 Regulates Gonadal Tumorigenesis Mol. Endocrinol., October 1, 2007; 21(10): 2472 - 2486. [Abstract] [Full Text] [PDF]

				B. D. Looyenga and G. D. Hammer Genetic Removal of Smad3 from Inhibin-Null Mice Attenuates Tumor Progression by Uncoupling Extracellular Mitogenic Signals from the Cell Cycle Machinery Mol. Endocrinol., October 1, 2007; 21(10): 2440 - 2457. [Abstract] [Full Text] [PDF]

				Q. Li, R. Kumar, K. Underwood, A. E. O'Connor, K. L. Loveland, J. S. Seehra, and M. M. Matzuk Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein Mol. Hum. Reprod., September 1, 2007; 13(9): 675 - 683. [Abstract] [Full Text] [PDF]

				C. Andreu-Vieyra, R. Chen, and M. M. Matzuk Effects of Granulosa Cell-Specific Deletion of Rb in Inha-{alpha} Null Female Mice Endocrinology, August 1, 2007; 148(8): 3837 - 3849. [Abstract] [Full Text] [PDF]

				P. C.K. Leung and J.-H. Choi Endocrine signaling in ovarian surface epithelium and cancer Hum. Reprod. Update, March 1, 2007; 13(2): 143 - 162. [Abstract] [Full Text] [PDF]

				E J Gold, X Zhang, A M Wheatley, S L Mellor, M Cranfield, G P Risbridger, N P Groome, and J S Fleming {beta}A- and {beta}C-activin, follistatin, activin receptor mRNA and {beta}C-activin peptide expression during rat liver regeneration J. Mol. Endocrinol., April 1, 2005; 34(2): 505 - 515. [Abstract] [Full Text] [PDF]

				K. Yoshinaga, H. Inoue, T. Utsunomiya, H. Sonoda, T. Masuda, K. Mimori, Y. Tanaka, and M. Mori N-Cadherin Is Regulated by Activin A and Associated with Tumor Aggressiveness in Esophageal Carcinoma Clin. Cancer Res., September 1, 2004; 10(17): 5702 - 5707. [Abstract] [Full Text] [PDF]

				C. A. Harrison, P. C. Gray, W. H. Fischer, C. Donaldson, S. Choe, and W. Vale An Activin Mutant with Disrupted ALK4 Binding Blocks Signaling via Type II Receptors J. Biol. Chem., July 2, 2004; 279(27): 28036 - 28044. [Abstract] [Full Text] [PDF]

				R. Rios, S. Fernandez-Nocelos, I. Carneiro, V. M. Arce, and J. Devesa Differential Response to Exogenous and Endogenous Myostatin in Myoblasts Suggests that Myostatin Acts as an Autocrine Factor in Vivo Endocrinology, June 1, 2004; 145(6): 2795 - 2803. [Abstract] [Full Text] [PDF]

				L. Cobellis, F. M. Reis, S. Luisi, S. Danero, L. Pirtoli, G. Scambia, and F. Petraglia High Concentrations of Activin A in the Peritoneal Fluid of Women With Epithelial Ovarian Cancer Reproductive Sciences, May 1, 2004; 11(4): 203 - 206. [Abstract] [PDF]

				C. W. Brown, L. Li, D. E. Houston-Hawkins, and M. M. Matzuk Activins Are Critical Modulators of Growth and Survival Mol. Endocrinol., December 1, 2003; 17(12): 2404 - 2417. [Abstract] [Full Text] [PDF]

				K. H. Burns, J. E. Agno, P. Sicinski, and M. M. Matzuk Cyclin D2 and p27 Are Tissue-Specific Regulators of Tumorigenesis in Inhibin {alpha} Knockout Mice Mol. Endocrinol., October 1, 2003; 17(10): 2053 - 2069. [Abstract] [Full Text] [PDF]

				K. H. Burns, J. E. Agno, L. Chen, B. Haupt, S. C. Ogbonna, K. S. Korach, and M. M. Matzuk Sexually Dimorphic Roles of Steroid Hormone Receptor Signaling in Gonadal Tumorigenesis Mol. Endocrinol., October 1, 2003; 17(10): 2039 - 2052. [Abstract] [Full Text] [PDF]

				F. Beuschlein, B. D. Looyenga, S. E. Bleasdale, C. Mutch, D. L. Bavers, A. F. Parlow, J. H. Nilson, and G. D. Hammer Activin Induces x-Zone Apoptosis That Inhibits Luteinizing Hormone-Dependent Adrenocortical Tumor Formation in Inhibin-Deficient Mice Mol. Cell. Biol., June 1, 2003; 23(11): 3951 - 3964. [Abstract] [Full Text] [PDF]

				H. Chang, C. W. Brown, and M. M. Matzuk Genetic Analysis of the Mammalian Transforming Growth Factor-{beta} Superfamily Endocr. Rev., December 1, 2002; 23(6): 787 - 823. [Abstract] [Full Text] [PDF]

				P. J. Fuller, E. T. Zumpe, S. Chu, P. Mamers, and H. G. Burger Inhibin-Activin Receptor Subunit Gene Expression in Ovarian Tumors J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1395 - 1401. [Abstract] [Full Text] [PDF]

				G. P. Risbridger, J. F. Schmitt, and D. M. Robertson Activins and Inhibins in Endocrine and Other Tumors Endocr. Rev., December 1, 2001; 22(6): 836 - 858. [Abstract] [Full Text] [PDF]

				S Wildi, J Kleeff, H Maruyama, C A Maurer, M W Buchler, and M Korc Overexpression of activin A in stage IV colorectal cancer Gut, September 1, 2001; 49(3): 409 - 417. [Abstract] [Full Text] [PDF]

				S. C. Cipriano, L. Chen, K. H. Burns, A. Koff, and M. M. Matzuk Inhibin and p27 Interact to Regulate Gonadal Tumorigenesis Mol. Endocrinol., June 1, 2001; 15(6): 985 - 996. [Abstract] [Full Text] [PDF]

				C. Yan and M. M. Matzuk Transgenic Models of Ovarian Failure Reproductive Sciences, January 1, 2001; 8(1_suppl): S30 - S33. [Abstract] [PDF]

				A. L. Lau, T. R. Kumar, K. Nishimori, J. Bonadio, and M. M. Matzuk Activin beta C and beta E Genes Are Not Essential for Mouse Liver Growth, Differentiation, and Regeneration Mol. Cell. Biol., August 15, 2000; 20(16): 6127 - 6137. [Abstract] [Full Text]

				T. M. Pierson, Y. Wang, F. J. DeMayo, M. M. Matzuk, S. Y. Tsai, and B. W. O’Malley Regulable Expression of Inhibin A in Wild-Type and Inhibin {alpha} Null Mice Mol. Endocrinol., July 1, 2000; 14(7): 1075 - 1085. [Abstract] [Full Text]

				S. C. Cipriano, L. Chen, T. R. Kumar, and M. M. Matzuk Follistatin Is a Modulator of Gonadal Tumor Progression and the Activin-Induced Wasting Syndrome in Inhibin-Deficient Mice Endocrinology, July 1, 2000; 141(7): 2319 - 2327. [Abstract] [Full Text] [PDF]

				W. Chen, T. K. Woodruff, and K. E. Mayo Activin A-Induced HepG2 Liver Cell Apoptosis: Involvement of Activin Receptors and Smad Proteins Endocrinology, March 1, 2000; 141(3): 1263 - 1272. [Abstract] [Full Text] [PDF]

				K. Takabe, J.-J. Lebrun, Y. Nagashima, Y. Ichikawa, M. Mitsuhashi, N. Momiyama, T. Ishikawa, H. Shimada, and W. W. Vale Interruption of Activin A Autocrine Regulation by Antisense Oligodeoxynucleotides Accelerates Liver Tumor Cell Proliferation Endocrinology, July 1, 1999; 140(7): 3125 - 3132. [Abstract] [Full Text]

				T. R. Kumar, G. Palapattu, P. Wang, T. K. Woodruff, I. Boime, M. C. Byrne, and M. M. Matzuk Transgenic Models to Study Gonadotropin Function: The Role of Follicle-Stimulating Hormone in Gonadal Growth and Tumorigenesis Mol. Endocrinol., June 1, 1999; 13(6): 851 - 865. [Abstract] [Full Text]

				F. Petraglia, P. Florio, S. Luisi, R. Gallo, A. Gadducci, P. Viganò, A. M. Di Blasio, A. R. Genazzani, and W. Vale Expression and Secretion of Inhibin and Activin in Normal and Neoplastic Uterine Tissues. High Levels of Serum Activin A in Women with Endometrial and Cervical Carcinoma J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1194 - 1200. [Abstract] [Full Text]

				Q. Li, S. M. Karam, K. A. Coerver, M. M. Matzuk, and J. I. Gordon Stimulation of Activin Receptor II Signaling Pathways Inhibits Differentiation of Multiple Gastric Epithelial Lineages Mol. Endocrinol., February 1, 1998; 12(2): 181 - 192. [Abstract] [Full Text]

				L. B. Draper, M. M. Matzuk, V. J. Roberts, E. Cox, J. Weiss, J. P. Mather, and T. K. Woodruff Identification of an Inhibin Receptor in Gonadal Tumors from Inhibin alpha -Subunit Knockout Mice J. Biol. Chem., January 2, 1998; 273(1): 398 - 403. [Abstract] [Full Text] [PDF]

				Q. Guo, T. R. Kumar, T. Woodruff, L. A. Hadsell, F. J. DeMayo, and M. M. Matzuk Overexpression of Mouse Follistatin Causes Reproductive Defects in Transgenic Mice Mol. Endocrinol., January 1, 1998; 12(1): 96 - 106. [Abstract] [Full Text]

				H. Lejeune, F. Chuzel, P. Sanchez, P. Durand, J. P. Mather, and J. M. Saez Stimulating Effect of Both Human Recombinant Inhibin A and Activin A on Immature Porcine Leydig Cell Functions in Vitro Endocrinology, November 1, 1997; 138(11): 4783 - 4791. [Abstract] [Full Text] [PDF]